205 related articles for article (PubMed ID: 23421897)
1. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.
Olsson B; Borgström L; Lundbäck H; Svensson M
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897
[TBL] [Abstract][Full Text] [Related]
2. Systemic availability and lung deposition of budesonide via three different nebulizers in adults.
Dahlström K; Thorsson L; Larsson P; Nikander K
Ann Allergy Asthma Immunol; 2003 Feb; 90(2):226-32. PubMed ID: 12602671
[TBL] [Abstract][Full Text] [Related]
3.
Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
[No Abstract] [Full Text] [Related]
4. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
Chrystyn H; Safioti G; Keegstra JR; Gopalan G
Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
[TBL] [Abstract][Full Text] [Related]
5. Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers.
Ruzycki CA; Murphy B; Nathoo H; Finlay WH; Martin AR
Pharm Res; 2020 Sep; 37(10):209. PubMed ID: 32995953
[TBL] [Abstract][Full Text] [Related]
6. An Exploration of Factors Affecting
Ruzycki CA; Martin AR; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
[No Abstract] [Full Text] [Related]
7. In vitro, ex vivo, in vivo veritas.
Borgström L
Allergy; 1999; 54 Suppl 49():88-92. PubMed ID: 10422754
[TBL] [Abstract][Full Text] [Related]
8. In vitro dose comparison of Respimat
Ciciliani AM; Langguth P; Wachtel H
Int J Chron Obstruct Pulmon Dis; 2017; 12():1565-1577. PubMed ID: 28603412
[TBL] [Abstract][Full Text] [Related]
9. InVitro Evaluation of Optimal Inhalation Flow Patterns for Commercial Dry Powder Inhalers and Pressurized Metered Dose Inhalers With Human Inhalation Flow Pattern Simulator.
Hira D; Okuda T; Mizutani A; Tomida N; Okamoto H
J Pharm Sci; 2018 Jun; 107(6):1731-1735. PubMed ID: 29428382
[TBL] [Abstract][Full Text] [Related]
10. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
Pitcairn G; Reader S; Pavia D; Newman S
J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
[TBL] [Abstract][Full Text] [Related]
11. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
[TBL] [Abstract][Full Text] [Related]
12. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
Delvadia RR; Longest PW; Hindle M; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
[TBL] [Abstract][Full Text] [Related]
13. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method.
Lähelmä S; Kirjavainen M; Kela M; Herttuainen J; Vahteristo M; Silvasti M; Ranki-Pesonen M
Br J Clin Pharmacol; 2005 Feb; 59(2):167-73. PubMed ID: 15676038
[TBL] [Abstract][Full Text] [Related]
14. Flow Structure and Particle Deposition Analyses for Optimization of a Pressurized Metered Dose Inhaler (pMDI) in a Model of Tracheobronchial Airway.
Ahookhosh K; Saidi M; Mohammadpourfard M; Aminfar H; Hamishehkar H; Farnoud A; Schmid O
Eur J Pharm Sci; 2021 Sep; 164():105911. PubMed ID: 34129919
[TBL] [Abstract][Full Text] [Related]
15. Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer.
Goldberg S; Einot T; Algur N; Schwartz S; Greenberg AC; Picard E; Virgilis D; Kerem E
Ann Allergy Asthma Immunol; 2002 Dec; 89(6):566-71. PubMed ID: 12487221
[TBL] [Abstract][Full Text] [Related]
16. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
Munzel U; Marschall K; Fyrnys B; Wedel M
Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
[TBL] [Abstract][Full Text] [Related]
17. A dry powder inhaler with reduced mouth-throat deposition.
Wang ZL; Grgic B; Finlay WH
J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.
Delvadia RR; Wei X; Longest PW; Venitz J; Byron PR
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):196-206. PubMed ID: 26447531
[TBL] [Abstract][Full Text] [Related]
19. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children.
Agertoft L; Pedersen S
Am J Respir Crit Care Med; 2003 Oct; 168(7):779-82. PubMed ID: 12893646
[TBL] [Abstract][Full Text] [Related]
20. Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers.
Tavernini S; Farina DJ; Martin AR; Finlay WH
Pharm Res; 2021 Sep; 38(9):1601-1613. PubMed ID: 34463937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
